Pharmasoft
Clinical trials sponsored by Pharmasoft, explained in plain language.
-
New Add-On therapy tested to slow Glaucoma's vision damage
Disease control CompletedThis study tested whether adding the drug Mexidol to standard glaucoma treatment could help protect the optic nerve and slow vision loss. It involved 80 people with advanced primary open-angle glaucoma whose eye pressure was already controlled. Researchers measured changes in eye…
Phase: PHASE4 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Apr 03, 2026 22:56 UTC
-
New glaucoma drug aims to shield eyes from irreversible damage
Disease control CompletedThis study tested whether a drug called Mexidol could help control primary open-angle glaucoma, a leading cause of irreversible blindness. Researchers compared different doses of the drug against a placebo in 102 patients with moderate to advanced stages of the disease. The main …
Phase: PHASE2 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for stroke recovery? drug aims to reduce lasting disability
Disease control CompletedThis study tested whether a drug called Mexidol®, when added to standard treatment, could help people recover better after an ischemic stroke. Over 300 patients who had recently suffered a stroke were given either the drug or a placebo for about 10 weeks. Researchers measured if …
Phase: PHASE3 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Brain blood flow drug aims to sharpen thinking and reduce fatigue
Disease control CompletedThis study tested whether a drug called Mexidol could help people with chronic reduced blood flow to the brain. Over 300 participants, aged 40-90 with mild thinking problems, received either the drug or a placebo. Researchers measured changes in memory, thinking skills, fatigue, …
Phase: PHASE3 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC